REG - Physiomics PLC - Appointment of Independent Non-Executive Director

PhysiomicsAnnouncement

29/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220329:nRSc3065Ga&default-theme=true

RNS Number : 3065G  Physiomics PLC  29 March 2022

29 March 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Physiomics appoints new Independent Non-Executive Director

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that Dr Tim Corn will join the Company's
board as an Independent Non-Executive Director from 1 April 2022.

Dr Tim Corn qualified in medicine at King's College Hospital and, after
becoming honorary Consultant and Senior Lecturer, joined the pharmaceutical
industry in 1983. He has held senior positions in both big and small pharma as
well as at the MHRA and became Chief Medical Officer ("CMO") of several small
but highly successful venture-backed companies, such as EUSA Pharma and Zeneus
Pharma. He has played a key role in more than twenty regulatory approvals in
the USA and Europe, is the author of more than forty scientific publications,
and was elected Fellow of both the Faculty of Pharmaceutical Medicine and the
Royal College of Psychiatrists. Tim previously served as Chairman and
Non-Executive Director on the Board of Reneuron plc (AIM: RENE), and currently
serves as a Trustee of Nerve Tumours UK, and as CMO of Nodenza Inc.

Dr Jim Millen, CEO, commented: "My colleagues and I are delighted to have been
able to attract someone of Tim's calibre and experience to our board of
directors. Tim is perfectly positioned to advise us on issues relating to our
core consulting business and has already provided valuable input into the
discussion of strategic initiatives through his participation in our advisory
board last year. I'd like to personally welcome Tim to the Company and look
forward to working with him going forwards."

 

Further information on Tim Corn's appointment:

The following details in relation to the appointment of Dr Timothy ("Tim")
Corn are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM
Rules:

Timothy Henry Corn (aged 70) has held the following directorships in the past
five years.

 

 Current Directorships / Partnerships  Past Directorships / Partnerships (last five years)
 Reneuron Group plc                    Neurocentrx Pharma Limited
 The Neurofibromatosis Association     Circassia Group PLC
 Zenios Bioscience LLP                 HERA
 Aesclepius Consulting Ltd
 Carter Communications Ltd
 Tots with Tumours Ltd
 Kids with Tumours Ltd
 Children with Tumours Ltd

 

There is no further information to be disclosed in relation to Tim Corn's
appointment pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii)
of the AIM Rules for Companies.

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFEDVRITFIF